Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMI1 | P35226 | 13/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.47 |
| ▸ | MTOR | P42345 | 6/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740851 | 0.92 | BMI1 (0.54) | BMI1PIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL16740876 | 0.91 | BMI1 (0.52) | BMI1PIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL16748621 | 0.90 | BMI1 (0.51) | BMI1PIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL16748479 | 0.89 | BMI1 (0.62) | BMI1PIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL16740798 | 0.88 | BMI1 (0.60) | BMI1PIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL16748607 | 0.88 | BMI1 (0.49) | BMI1PIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL16740827 | 0.87 | BMI1 (0.65) | BMI1 | |
| SCHEMBL16740754 | 0.87 | BMI1 (0.55) | BMI1 | |
| SCHEMBL16740714 | 0.86 | BMI1 (0.50) | BMI1PIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL16740874 | 0.86 | BMI1 (0.50) | BMI1PIK3CAMTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | claimed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | claimed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | BMI1 1/4885PIK3CA 3534/4885MTOR 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.